ArticleScientific reports2026
A patient-specific induced pluripotent stem cell and neural stem cell resource for angelman syndrome with 15q11.2-q13 deletion.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Angelman syndrome (AS) is a severe neurodevelopmental disorder most commonly caused by a maternal deletion of the 15q11.2-q13 region, resulting in loss of ubiquitin protein ligase E3A (UBE3A) function. The development of targeted therapies and a deeper understanding of AS pathogenesis require the availability of genetically accurate human models. Here, we generated and characterized a novel induced pluripotent stem cell (iPSC) line from peripheral blood mononuclear cells of a female pediatric patient with genetically confirmed deletion-type AS. The iPSC line displayed a normal karyotype, expressed key pluripotency markers, and demonstrated trilineage differentiation potential. Efficient generation of neural stem cells establishes a foundational cellular resource for future investigations of neuronal maturation and disease-specific phenotypes. This well-validated iPSC and NSC resource provides a valuable and clinically relevant platform for elucidating the molecular pathophysiology of AS in a genetically accurate human cellular context and for high-throughput screening of therapeutic compounds targeting the predominant population of patients with AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.